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L E T T E R  T O  T H E  E D I T O R
Do congenital bleeding disorders have a protective effect 
against COVID-19? A prospective study
Dear Editor,
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
infection is the most common medical challenge around the world 
at this time, having infected about 30 million people, and caused 
hundreds of thousands of deaths.1 The infection has various ef-
fects on the patient's life; those with underlying diseases are more 
prone to the severe form of the disorder.2,3 Coagulopathy, most 
commonly hypercoagulability, is a prominent feature of coronavi-
rus disease 2019 (COVID-19).3 Although less common, hemorrhage 
is another serious complication. About one-third of deaths have 
been attributed to thrombotic events,4 and thrombotic complica-
tions frequently have been observed among patients hospitalized 
with COVID-19, even in those under anticoagulation.3,4 Congenital 
bleeding disorders (CBDs) are accompanied by various underly-
ing disorders, including cardiovascular diseases, potentially making 
them more susceptible to the severe form of COVID-19.5 The effect 
of a disease with a hypercoagulable state on patients with inherited 
hypocoagulability is illuminating. Only a few case reports and small 
case series are available in this context.6,7 Our primary observation 
revealed a more favorable outcome of COVID-19 on patients with 
CBDs.6 We found a protective effect on patients with CBDs against 
COVID-19 hypercoagulability and therefore a lower rate of morbid-
ity and mortality. In the present study, we prospectively assessed 
the patients with CBDs infected by SARS-CoV-2 infection.
This prospective study was conducted on patients with CBDs 
from June 2020 to September 2020. The study was approved by 
the ethical committee of Shahid Beheshti University of Medical 
Sciences, and written consent was obtained from all participants. All 
patients with CBDs who were referred to the Iranian Comprehensive 
Hemophilia Care Center (ICHCC) for their routine check-up, prophy-
laxis, or on-demand therapy were included in the study. All patients 
were checked for body temperature, and oxygen saturation (SpO2) 
using pulse oximetry and were interviewed about signs and symp-
toms of COVID-19. All patients were checked by complete blood 
count (CBC) (Sysmex kx_21 haematology analyser), C-reactive pro-
tein (CRP) (Mindray Chemistry Analyzer; BS-200), and SARS-COV-2 
immunoglobulin (Ig) G, and IgM. All suspected patients, based on 
results of the tests and clinical presentations, were assessed by re-
verse transcriptase–polymerase chain reaction (RT-PCR) for SARS-
CoV-2 infection. Those with positive RT-PCR, and/or SARS-CoV-2 
antibody, were considered positive for COVID-19. Those with posi-
tive RT-PCR were followed until symptoms resolved and a negative 
RT-PCR was obtained. In addition, during the study period, data of 
other patients affected by CBDs and a positive RT-PCR throughout 
the country were collected.
During the study period, we followed 61 patients: 46 with posi-
tive RT-PCR, 15 with positive SARS-CoV-2 IgG (of whom 6 also were 
positive for SARS-CoV-2 IgM). Forty-nine (~80%) patients were male, 
and 12 were female. Mean age of the patients was 35.3 years (rang-
ing from 2 months to 66 years). These included 33 patients with he-
mophilia A (HA) (55%), 9 hemophilia B (HB) (15%), 9 von Willebrand 
disease (VWD) (15%), 4 factor (F) X deficiency (6.6%), 2 FV deficiency 
(3.3%), 2 FVII deficiency (1.7%), 1 platelet function disorder (1.7%), 
1 vitamin K-dependent coagulation factor (VKCF) deficiency (1.7%). 
Most patients (n: 27, ~82%) had severe (FVIII:C < 1%) HA, while 6 
had mild (FVIII:C > 5%) HA. The majority of HB (n: 7, ~78%) had the 
severe form of the disorder. Six patients (~66%) had type 3 VWD, 
while the remaining (~33%) had type 1 VWD. Three of 4 patients 
with FX deficiency had severe (FX:C < 1%) deficiency, while both 
patients with FV deficiency had mild factor deficiency (FV:C > 30%) 
(Table 1).
Two patients, one type 3 VWD and one severe HA, had a high-ti-
ter inhibitor (>5 Bethesda units). The majority of patients had a 
mild course of SARS-CoV-2 infection (14 asymptomatic, 38 mild 
symptoms), while 9 required hospitalization, including 3 in inten-
sive care units. No death was observed during the study period, 
nor any thrombotic event reported. Within the study population, 
2 patients had cardiovascular disease, one diabetes, one diabetes 
and hepatitis B, one hypothyroidism, and one thyroidectomy. The 
symptomatic patients experienced fever (~53%), sore throat (~28%), 
and myalgia (~28%). Shortness of breath (15.6%), loss of smell and 
taste (15.6%), headache (12.5%), fatigue (12.5%), coughing (12.5%), 
diarrhea (12.5%), vomiting (9.4%), and abdominal pain (6.2%) were 
other symptoms. Eleven patients (18.35%) received prophylaxis, 
while the rest received on-demand therapy. Of the five patients with 
hemarthrosis, all but one had severe HA. Menorrhagia occurred in 
one female carrier of HA. Two patients with VWD, type 1 and 3, 
experienced epistaxis.
This prospective study identified 61 patients with COVID-19:46 
with positive RT-PCR and 15 with a positive IgG. No patient experi-
enced a thrombotic event over the course of the study. Hemorrhagic 
events did take place, but only in patients receiving on-demand re-
placement therapy. Moreover, all bleeds but one occurred in patients 
with severe CBDs, among whom this rate of bleeding can be consid-
ered normal. The overall mortality rate of COVID-19 in the general 
population is ~3%.8 Not one death has occurred among the ~12 000 



































36.1 6/3 Asymptomatic: ~67% Epistaxis: ~22%







15.3 2/2 Asymptomatic: 25% —
Cough: 50%




FVD Mild: 2 42.4 1/1 — Epistaxis: 50%




VKCFD Mild 37 Female Shortness of breath —
Myalgia
Fever
IPFD NA 45 Female NA NA
Abbreviations: FVD, Factor V deficiency; FVIID, Factor VII deficiency; HA, Hemophilia A; HB, 
Hemophilia B; IPFD, Inherited platelet function disorder; NA, Not available; VKCFD, Vitamin K 
dependent deficiency; VWD, von Willebrand disease.
aSymptomatic patients. 
bAll patients. 
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Iranian patients with CBDs since the pandemic's onset, appearing to 
show a potential protective effect against COVID-19 on patients with 
CBDs.6 In an earlier study, we reported a patient with type 1 VWD 
and a thrombotic event 6; this did not occur in the study at hand. Since 
thrombotic events are among the leading causes of death in patients 
with COVID-19, absence of thrombosis significantly decreases the 
rate of mortality, as observed in this study. The majority of patients 
have had a mild COVID-19 related phenotype, as has been reported 
elsewhere.9 Our hypothesis was that CBD patients with moder-
ate-to-severe deficiency are protected against COVID-19-related 
hypercoagulability. This study showed that the rate of COVID-19 is 
not low among patients with CBDs, who probably are enjoying a fa-
vorable outcome. A considerable number of patients with CBDs and 
COVID-19 are asymptomatic, as in the general population.
The international society of thrombosis and hemostasis (ISTH) 
recommended anticoagulation for all hospitalized patients to fore-
stall thrombotic morbidity or mortality.10 Our data demonstrated 
that hypocoagulability plays a major role in decreasing the rate of 
morbidity and mortality in patients with COVID-19, emphasizing the 
role of anticoagulation therapy, despite controversial reports on the 
effectiveness of anticoagulation.11,12
Although some types of CBDs have a propensity to thrombotic 
events, most present a state of general hypocoagulability, making 
patients less prone to thrombotic events, even in COVID-19, which 
has a tendency to a state of hypercoagulability.6 In patients with 
VWD, particularly type III, pulmonary thrombosis—proposed as the 
main pulmonary complication in COVID-19—really is less probable. 
Moreover, a venous thromboembolism (VTE), particularly deep vein 
thrombosis (DVT), as a common complication of COVID-19, is less 
likely in patients whose severe factor deficiency interrupts the co-
agulation cascade.4
Our other study also revealed that even COVID-19 can increase 
acute phase reactants, including coagulation factors, lessening the 
severity of the bleeding tendency, a phenomenon that could be 
named a “reciprocal effect.”
During the study period, the seven patients who were under reg-
ular prophylaxis did not experience a more serious course of COVID-
19. It appears that replacement therapy does not eliminate the 
CBD-related protective effect. A replacement therapy that raises the 
deficient factor level to normal range might eliminate this protective 
effect. A more flexible replacement therapy could be considered. 
Although data of the present study are valuable, further studies on 
a large number of patients are require to answer all questions about 
the effects of COVID-19 on the life of patients with CBDs.
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